Showing results (181-190 of 211) with videos related to
Sort By:
Pageof 22
Journal of Surgical Oncology|September 2, 2009
Lipopolysaccharide (LPS) increases the invasive ability of pancreatic cancer cells through the TLR4/MyD88 signaling pathwayMio Ikebe, Yoshiki Kitaura, Masafumi Nakamura, et al.European Journal of Haematology|August 23, 2006
Hypogammaglobulinemia with a selective delayed recovery in memory B cells and an impaired isotype expression after rituximab administration as an adjuvant to autologous stem cell transplantation for non-Hodgkin lymphomaMitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, et al.British Journal of Haematology|April 26, 2007
Delayed redistribution of CD27, CD40 and CD80 positive B cells and the impaired in vitro immunoglobulin production in patients with non-Hodgkin lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantationMitsufumi Nishio, Katsuya Fujimoto, Satoshi Yamamoto, et al.BMJ Open|February 2, 2023
Protocol for treating lumbar spinal canal stenosis with a combination of ultrapurified, allogenic bone marrow-derived mesenchymal stem cells and in situ-forming gel: a multicentre, prospective, double-blind randomised controlled trialHideki Sudo, Takashi Miyakoshi, Yudai Watanabe, et al.Molecular & Cellular Proteomics : MCP|October 11, 2005
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approachMads Grønborg, Troels Zakarias Kristiansen, Akiko Iwahori, et al.BMJ Open|February 9, 2021
Multiple system atrophy in Hokkaido, Japan: a prospective registry study of natural history and symptom assessment scales followed for 5 yearsMasaaki Matsushima, Ichiro Yabe, Ken Sakushima, et al.BMJ Open Gastroenterology|June 20, 2018
Evaluation of amnion-derived mesenchymal stem cells for treatment-resistant moderate Crohn's disease: study protocol for a phase I/II, dual-centre, open-label, uncontrolled, dose-response trialShinsuke Otagiri, Shunsuke Ohnishi, Arisa Miura, et al.Stroke|May 22, 2023
Five-Year Stroke Risk and Its Predictors in Asymptomatic Moyamoya Disease: Asymptomatic Moyamoya Registry (AMORE)Satoshi Kuroda, Shusuke Yamamoto, Takeshi Funaki, et al.The Journal of Investigative Dermatology|May 6, 2019
Cultured Epidermal Autografts from Clinically Revertant Skin as a Potential Wound Treatment for Recessive Dystrophic Epidermolysis BullosaWakana Matsumura, Yasuyuki Fujita, Satoru Shinkuma, et al.Journal of Neurosurgery|May 14, 2025
Disease progression, transient ischemic attack, and de novo parenchymal lesions in asymptomatic moyamoya disease: results of a 5-year interim analysis of the AMORE studySatoshi Kuroda, Shusuke Yamamoto, Takeshi Funaki, et al.Pageof 22